<?xml version="1.0" encoding="UTF-8"?><?xml-model type="application/xml-dtd" href="https://jats.nlm.nih.gov/publishing/1.3/JATS-journalpublishing1-3.dtd"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "https://jats.nlm.nih.gov/publishing/1.3/JATS-journalpublishing1-3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" specific-use="Marcalyc 1.3" dtd-version="1.3" article-type="editorial" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="index">6920</journal-id>
<journal-title-group>
<journal-title specific-use="original" xml:lang="en">Iberoamerican Journal of Medicine</journal-title>
<abbrev-journal-title abbrev-type="publisher" xml:lang="en">Iberoam J Med</abbrev-journal-title>
</journal-title-group>
<issn pub-type="epub">2695-5075</issn>
<issn-l>2695-5075</issn-l>
<publisher>
<publisher-name>Hospital San Pedro</publisher-name>
<publisher-loc>
<country>España</country>
<email>eestebanz@riojasalud.es</email>
</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="art-access-id" specific-use="redalyc">692082831001</article-id>
<article-id pub-id-type="doi">10.53986/ibjm.2025.0013</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Editorial</subject>
</subj-group>
</article-categories>
<title-group>
<article-title xml:lang="en">Recommendations for Exacerbations of Superinfected Bronchiectasis by Pseudomonas. What about quaternary prevention?</article-title>
<trans-title-group>
<trans-title xml:lang="es">Recomendaciones para las exacerbaciones de bronquiectasias superinfectadas por Pseudomonas. ¿Qué hay de la prevención cuaternaria?</trans-title>
</trans-title-group>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8743-1513</contrib-id>
<name name-style="western">
<surname>Ramón-Trapero</surname>
<given-names>José Luis</given-names>
</name>
<xref ref-type="corresp" rid="corresp1"/>
<xref ref-type="aff" rid="aff1"/>
<email>josoramon@hotmail.com</email>
</contrib>
<contrib contrib-type="author" corresp="no">
<name name-style="western">
<surname>Sánchez Diaz-Aldagalán</surname>
<given-names>Yolanda</given-names>
</name>
<xref ref-type="aff" rid="aff3"/>
</contrib>
<contrib contrib-type="author" corresp="no">
<name name-style="western">
<surname>Lacalle-Navaridas</surname>
<given-names>Sara</given-names>
</name>
<xref ref-type="aff" rid="aff5"/>
</contrib>
<contrib contrib-type="author" corresp="no">
<name name-style="western">
<surname>Ortega-Martinez</surname>
<given-names>Jesus</given-names>
</name>
<xref ref-type="aff" rid="aff7"/>
</contrib>
</contrib-group>
<aff id="aff1">
<institution content-type="original"> Family Medicine, Working Group of infectious diseases of SrMFYC (Riojan society of family and community medicine), Spain </institution>
<country country="ES">España</country>
<institution-wrap>
<institution content-type="orgname"> Working Group of infectious diseases of SrMFYC (Riojan society of family and community medicine) </institution>
</institution-wrap>
</aff>
<aff id="aff3">
<institution content-type="original"> Family Medicine, Working Group of infectious diseases of SrMFYC (Riojan society of family and community medicine), Spain </institution>
<country country="ES">España</country>
<institution-wrap>
<institution content-type="orgname"> Working Group of infectious diseases of SrMFYC (Riojan society of family and community medicine) </institution>
</institution-wrap>
</aff>
<aff id="aff5">
<institution content-type="original"> Family Medicine, Working Group of infectious diseases of SrMFYC (Riojan society of family and community medicine), Spain </institution>
<country country="ES">España</country>
<institution-wrap>
<institution content-type="orgname"> Working Group of infectious diseases of SrMFYC (Riojan society of family and community medicine) </institution>
</institution-wrap>
</aff>
<aff id="aff7">
<institution content-type="original"> Family Medicine, Working Group of infectious diseases of SrMFYC (Riojan society of family and community medicine), Spain </institution>
<country country="ES">España</country>
<institution-wrap>
<institution content-type="orgname"> Working Group of infectious diseases of SrMFYC (Riojan society of family and community medicine) </institution>
</institution-wrap>
</aff>
<author-notes>
<corresp id="corresp1">
<email>josoramon@hotmail.com</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<year>2025</year>
</pub-date>
<volume>7</volume>
<issue>2</issue>
<fpage>32</fpage>
<lpage>34</lpage>
<history>
<date date-type="received" publication-format="dd mes yyyy">
<day>28</day>
<month>02</month>
<year>2025</year>
</date>
<date date-type="corrected" publication-format="dd mes yyyy">
<day>09</day>
<month>04</month>
<year>2025</year>
</date>
<date date-type="accepted" publication-format="dd mes yyyy">
<day>23</day>
<month>04</month>
<year>2025</year>
</date>
</history>
<permissions>
<ali:free_to_read/>
</permissions>
<kwd-group xml:lang="en">
<title>Keywords</title>
<kwd>Quaternary prevention</kwd>
<kwd>Azithromycin</kwd>
<kwd>Bronchiectasis</kwd>
<kwd>Macrolides</kwd>
<kwd>Superinfection</kwd>
<kwd>
<italic>Pseudomonas aeruginosa</italic>
</kwd>
</kwd-group>
<kwd-group xml:lang="es">
<title>Palabras clave</title>
<kwd>Prevención cuaternaria </kwd>
<kwd>Azitromicina</kwd>
<kwd>Bronquiectasias</kwd>
<kwd>Macrólidos</kwd>
<kwd>Superinfección</kwd>
<kwd>
<italic>Pseudomonas aeruginosa</italic>
</kwd>
</kwd-group>
<counts>
<fig-count count="0"/>
<table-count count="0"/>
<equation-count count="0"/>
<ref-count count="9"/>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>redalyc-journal-id</meta-name>
<meta-value>6920</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec>
<title/>
<p>Quaternary prevention is the set of measures taken to avoid, reduce, or alleviate the harm caused by healthcare activities [<xref ref-type="bibr" rid="redalyc_692082831001_ref1">1</xref>]. An identical idea to the Hippocratic message of "non nocere" (do no harm) and although it now seems to be very fashionable (multiple campaigns promoting "Not to do", "deprescribing", "rational use of medications"...) quaternary prevention is a concept that has not received much attention until recent years ("quaternary prevention" was not included as a MeSH term until 2020) [<xref ref-type="bibr" rid="redalyc_692082831001_ref2">2</xref>].</p>
<p>Although the concept is accepted without any opposition among professionals, in our daily practice we find ourselves immersed in clinical actions that call into question (unintentionally, of course) quaternary prevention [<xref ref-type="bibr" rid="redalyc_692082831001_ref1">1</xref>]. In addition, not only due to decisions made in personal actions. We also incur this by following the recommendations of clinical guidelines based on scarce evidence and/or not adjusted to the reality of the patients we treat in our daily practice.</p>
<p>This is the case, for example, of the recommendation given for patients with superinfected bronchiectasis by <italic>Pseudomonas aeruginosa</italic> with recurrent episodes. Several summaries reflect that the preventive method of choice is the intake of Azithromycin 500 mg three times a week or 250 mg daily [<xref ref-type="bibr" rid="redalyc_692082831001_ref3">3</xref>, <xref ref-type="bibr" rid="redalyc_692082831001_ref4">4</xref>]. The authors base their recommendations on the studies available so far, some with adjusted sample sizes and/or with the inclusion of patients with different characteristics from those, we can manage in our consultations. In these texts, the advantages and disadvantages of the treatment are explicitly narrated, with the authors clearly positioning themselves in favor of the recommendation [<xref ref-type="bibr" rid="redalyc_692082831001_ref4">4</xref>]. Among the comments they provide, it´s surprising that although the reviewed studies have been designed for 6 and 12 months [<xref ref-type="bibr" rid="redalyc_692082831001_ref5">5</xref>], they advise maintaining the treatment "indefinitely." There is no record that they base this decision on any specific data or finding in the literature, so we understand therefore that it resembles a recommendation as expert opinion (remember that in the evidence level pyramid, expert opinion is at the lowest levels) [<xref ref-type="bibr" rid="redalyc_692082831001_ref6">6</xref>]. They explain the reduction of exacerbations among those taking azithromycin versus those taking placebo (there do not seem to be studies comparing the macrolide with another medication). However, the information does not end there: the authors show great sensibility and honesty in detailing the problems that this therapy can entail. They explain that not everything is improvement for the patient [<xref ref-type="bibr" rid="redalyc_692082831001_ref3">3</xref>, <xref ref-type="bibr" rid="redalyc_692082831001_ref4">4</xref>, <xref ref-type="bibr" rid="redalyc_692082831001_ref7">7</xref>].</p>
<p> Pulmonary function and quality of life remain unchanged whether they take placebo or antibiotic;</p>
<p> The rates of colonization by germs resistant to Azithromycin skyrocket;</p>
<p> Cases of diarrhea, abdominal pain, and other gastrointestinal discomfort increase;</p>
<p> Hepatotoxicity may appear;  Cases of decreased hearing have been described;</p>
<p> Moreover, as a group effect, not only of azithromycin, the authors recall that prolonged use of macrolides can be related to a higher rate of cardiovascular events (prolongation of the QT interval, hypokalemia, hypomagnesemia, significant bradycardia, bradyarrhythmias, or decompensated heart failure). </p>
<p>If we reflect on the characteristics of the patients who usually present superinfection of bronchiectasis by <italic>P. aeruginosa</italic> with exacerbations, they are generally elderly, frail, polymedicated patients with multiple comorbidities [<xref ref-type="bibr" rid="redalyc_692082831001_ref1">1</xref>]. Initially, these do not seem to be the ideal candidates to subject them to the risk that the indefinite consumption of azithromycin seems to entail with the undesirable effects that it can produce.</p>
<p>With this comment, we do not intend to question any of these summaries; do not understand it this way. We congratulate and applaud the quality of the review by the authors of the main clinical guidelines in this field, the recommendation documents and the summaries. We know how complicated it is to review a topic of these characteristics. However, if we respect and do not forget what the term “quaternary prevention” entails [<xref ref-type="bibr" rid="redalyc_692082831001_ref1">1</xref>], doubts and questions arise as to whether actions as apparently risky as this are sufficiently justified in patients as weak as these [<xref ref-type="bibr" rid="redalyc_692082831001_ref1">1</xref>].</p>
<p>We therefore consider it important to keep quaternary prevention very much in mind in our daily work. It is obvious that at the professional level we must demand of ourselves continuing education and provide the best possible care for our patients. However, we must also be self-critical and individualized when it comes to prescribing treatments or exposing patients to clinical tests or complementary examinations. Quaternary prevention must always prevail in the practice of our profession and we physicians must respect what this concept implies. We must remain alert so as not to indiscriminately accept everything that the clinical guidelines and recommendations indicate, choosing which patients and at what times it may benefit them or, on the contrary, put them at risk. Only in this way will we be able to work keeping on the horizon the idea of achieving the maximum benefit for our patients [<xref ref-type="bibr" rid="redalyc_692082831001_ref1">1</xref>, <xref ref-type="bibr" rid="redalyc_692082831001_ref8">8</xref>, <xref ref-type="bibr" rid="redalyc_692082831001_ref9">9</xref>].</p>
</sec>
<sec>
<title>
<bold> CONFLICT OF INTERESTS </bold>
</title>
<p>The authors have no conflict of interest to declare. The authors declared that this study has received no financial support.</p>
</sec>
</body>
<back>
<ref-list>
<title>REFERENCES</title>
<ref id="redalyc_692082831001_ref1">
<mixed-citation publication-type="journal">
<italic>1. Gérvas J. [Quaternary prevention in the elderly]. Rev Esp Geriatr Gerontol. 2012;47(6):266-9. doi: 10.1016/j.regg.2012.07.001. </italic>
</mixed-citation>
<element-citation publication-type="journal">
<article-title>[Quaternary prevention in the elderly]</article-title>
<source>Gérvas J. [Quaternary prevention in the elderly]. Rev Esp Geriatr Gerontol. 2012;47(6):266-9. doi: 10.1016/j.regg.2012.07.001</source>
<year>2012</year>
</element-citation>
</ref>
<ref id="redalyc_692082831001_ref2">
<mixed-citation publication-type="webpage">
<italic>2. NCBI. Quaternary Prevention. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/mesh/?term=quaternary+prevention">https://www.ncbi.nlm.nih.gov/mesh/?term=quaternary+prevention</ext-link> (accessed Feb 2025). </italic>
</mixed-citation>
<element-citation publication-type="webpage">
<source>NCBI. Quaternary Prevention. Available from: https://www.ncbi.nlm.nih.gov/mesh/?term=quaternary+prevention (accessed Feb 2025)</source>
<year>2025</year>
<comment>
<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/mesh/?term=quaternary+prevention">https://www.ncbi.nlm.nih.gov/mesh/?term=quaternary+prevention</ext-link>
</comment>
</element-citation>
</ref>
<ref id="redalyc_692082831001_ref3">
<mixed-citation publication-type="journal">
<italic>3. Polverino E, Goeminne PC, McDonnell MJ, Aliberti S, Marshall SE, Loebinger MR, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J. 2017;50(3):1700629. doi: 10.1183/13993003.00629-2017. </italic>
</mixed-citation>
<element-citation publication-type="journal">
<article-title>European Respiratory Society guidelines for the management of adult bronchiectasis</article-title>
<source>Polverino E, Goeminne PC, McDonnell MJ, Aliberti S, Marshall SE, Loebinger MR, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J. 2017;50(3):1700629. doi: 10.1183/13993003.00629-2017</source>
<year>2017</year>
</element-citation>
</ref>
<ref id="redalyc_692082831001_ref4">
<mixed-citation publication-type="database">
<italic>4. Barker A. Bronchiectasis in adults: Maintaining lung health. Available from: <ext-link ext-link-type="uri" xlink:href="https://www-uptodate-com.lo-hsp.a17.csinet.es/contents/bronchiectasis-in-adults-maintaining-lung-health?search=bronquiectasias&amp;source=search_result&amp;selectedTitle=3%7E150&amp;usage_type=default&amp;display_rank=3">https://www-uptodate-com.lo-hsp.a17.csinet.es/contents/bronchiectasis-in-adults-maintaining-lung-health?search=bronquiectasias&amp;source=search_result&amp;selectedTitle=3%7E150&amp;usage_type=default&amp;display_rank=3</ext-link> (accessed Feb 2025). </italic>
</mixed-citation>
<element-citation publication-type="database">
<source>Barker A. Bronchiectasis in adults: Maintaining lung health. Available from: https://www-uptodate-com.lo-hsp.a17.csinet.es/contents/bronchiectasis-in-adults-maintaining-lung-health?search=bronquiectasias&amp;source=search_result&amp;selectedTitle=3%7E150&amp;usage_type=default&amp;display_rank=3 (accessed Feb 2025)</source>
<year>2025</year>
<comment>
<ext-link ext-link-type="uri" xlink:href="https://www-uptodate-com.lo-hsp.a17.csinet.es/contents/bronchiectasis-in-adults-maintaining-lung-health?search=bronquiectasias&amp;source=search_result&amp;selectedTitle=3%7E150&amp;usage_type=default&amp;display_rank=3">https://www-uptodate-com.lo-hsp.a17.csinet.es/contents/bronchiectasis-in-adults-maintaining-lung-health?search=bronquiectasias&amp;source=search_result&amp;selectedTitle=3%7E150&amp;usage_type=default&amp;display_rank=3</ext-link>
</comment>
</element-citation>
</ref>
<ref id="redalyc_692082831001_ref5">
<mixed-citation publication-type="journal">
<italic>5. Nakagawa N, Ito M, Asakura T, Horita N, Obase Y, Mukae H. Efficacy and safety of long-term macrolide therapy for non-cystic fibrosis bronchiectasis: A systematic review and meta-analysis. Respir Investig. 2024;62(6):1079-1087. doi: 10.1016/j.resinv.2024.09.004. </italic>
</mixed-citation>
<element-citation publication-type="journal">
<article-title>Efficacy and safety of long-term macrolide therapy for non-cystic fibrosis bronchiectasis: A systematic review and meta-analysis</article-title>
<source>Nakagawa N, Ito M, Asakura T, Horita N, Obase Y, Mukae H. Efficacy and safety of long-term macrolide therapy for non-cystic fibrosis bronchiectasis: A systematic review and meta-analysis. Respir Investig. 2024;62(6):1079-1087. doi: 10.1016/j.resinv.2024.09.004</source>
<year>2024</year>
</element-citation>
</ref>
<ref id="redalyc_692082831001_ref6">
<mixed-citation publication-type="journal">
<italic>6. Manterola C, Asenjo-Lobos C, Otzen T. [Hierarchy of evidence: levels of evidence and grades of recommendation from current use]. Rev Chilena Infectol. 2014;31(6):705-18. doi: 10.4067/S0716-10182014000600011. </italic>
</mixed-citation>
<element-citation publication-type="journal">
<article-title>[Hierarchy of evidence: levels of evidence and grades of recommendation from current use]</article-title>
<source>Manterola C, Asenjo-Lobos C, Otzen T. [Hierarchy of evidence: levels of evidence and grades of recommendation from current use]. Rev Chilena Infectol. 2014;31(6):705-18. doi: 10.4067/S0716-10182014000600011</source>
<year>2014</year>
</element-citation>
</ref>
<ref id="redalyc_692082831001_ref7">
<mixed-citation publication-type="journal">
<italic>7. Kelly C, Chalmers JD, Crossingham I, Relph N, Felix LM, Evans DJ, et al. Macrolide antibiotics for bronchiectasis. Cochrane Database Syst Rev. 2018;3(3):CD012406. doi: 10.1002/14651858.CD012406.pub2. </italic>
</mixed-citation>
<element-citation publication-type="journal">
<article-title>Macrolide antibiotics for bronchiectasis</article-title>
<source>Kelly C, Chalmers JD, Crossingham I, Relph N, Felix LM, Evans DJ, et al. Macrolide antibiotics for bronchiectasis. Cochrane Database Syst Rev. 2018;3(3):CD012406. doi: 10.1002/14651858.CD012406.pub2</source>
<year>2018</year>
</element-citation>
</ref>
<ref id="redalyc_692082831001_ref8">
<mixed-citation publication-type="journal">
<italic>8. Otte JA, Llargués Pou M. Enablers and barriers to a quaternary prevention approach: a qualitative study of field experts. BMJ Open. 2024;14(3):e076836. doi: 10.1136/bmjopen-2023-076836. </italic>
</mixed-citation>
<element-citation publication-type="journal">
<article-title>Enablers and barriers to a quaternary prevention approach: a qualitative study of field experts</article-title>
<source>Otte JA, Llargués Pou M. Enablers and barriers to a quaternary prevention approach: a qualitative study of field experts. BMJ Open. 2024;14(3):e076836. doi: 10.1136/bmjopen-2023-076836</source>
<year>2024</year>
</element-citation>
</ref>
<ref id="redalyc_692082831001_ref9">
<mixed-citation publication-type="journal">
<italic>9. Norman AH, Tesser CD. Quaternary prevention: a balanced approach to demedicalisation. Br J Gen Pract. 2019;69(678):28-9. doi: 10.3399/bjgp19X700517.</italic>
</mixed-citation>
<element-citation publication-type="journal">
<article-title>Quaternary prevention: a balanced approach to demedicalisation</article-title>
<source>Norman AH, Tesser CD. Quaternary prevention: a balanced approach to demedicalisation. Br J Gen Pract. 2019;69(678):28-9. doi: 10.3399/bjgp19X700517</source>
<year>2019</year>
</element-citation>
</ref>
</ref-list>
</back>
</article>